Leaderboards/Liver Disease and Transplantation

Liver Disease and Transplantation

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Papers

Periportal macrophages protect against commensal-driven liver inflammation

Nature|2024

112 cit.

Publication in Scientific Reports (2025) [76 citations, W4408062005]

Scientific Reports|2025

76 cit.

Publication in Frontiers in Immunology (2024) [20 citations, W4391359076]

Frontiers in Immunology|2024

20 cit.

Publication in Microbiological Research (2025) [11 citations, W4407439061]

Microbiological Research|2025

11 cit.

Publication in Journal of Neuroimmune Pharmacology (2024) [10 citations, W4403272004]

Journal of Neuroimmune Pharmacology|2024

10 cit.

Golexanolone reduces glial activation in the striatum and improves non-motor and some motor alterations in a rat model of Parkinson's disease

Frontiers in Aging Neuroscience|2024

9 cit.

Management of varices but not anticoagulation is associated with improved outcome in patients with HCC and macrovascular tumour invasion

Cancer Imaging|2024

8 cit.

Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy

Frontiers in Oncology|2024

6 cit.

A systematic <scp>PCR</scp> record‐based re‐call of <scp>HCV</scp>‐<scp>RNA</scp>‐positive people enables re‐linkage to care and <scp>HCV</scp> elimination in Austria — The <scp>ELIMINATE</scp> project

Liver International|2024

6 cit.

Risk of portal hypertensive complications preventable by TIPS in patients with ascites

JHEP Reports|2025

4 cit.

Emerging Leaders

Drafting the new consensus

Researchers

Xingshun Qi

General Hospital of Shenyang Military Region

Mattias Mandorfer

Medical University of Vienna

Giacomo Zaccherini

Azienda USL di Bologna

Benjamin Maasoumy

Medizinische Hochschule Hannover

Mazen Noureddin

Methodist Hospital

Sherief Abd‐Elsalam

University of Washington

Rohit Loomba

University of California San Diego

Núria Ramos

Centre National de la Recherche Scientifique

Ilaria Di Bartolo

Istituto Superiore di Sanità

Yulia Savva

Ithaka Harbors

Papers

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

Journal of Hepatology|2022

209 cit.

Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017–2020

Clinical Gastroenterology and Hepatology|2023

208 cit.

Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels

Journal of Hepatology|2022

122 cit.

Efruxifermin in Compensated Liver Cirrhosis Caused by MASH

New England Journal of Medicine|2025

91 cit.

Non-invasive tests for clinically significant portal hypertension after HCV cure

Journal of Hepatology|2022

84 cit.

Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017–2018 transient elastography data and application of machine learning

Hepatology Communications|2022

81 cit.

Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD‐related cirrhosis

Hepatology|2022

80 cit.

The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension

Clinical Gastroenterology and Hepatology|2022

80 cit.

Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)

Hepatology|2023

71 cit.

Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)

Wiener klinische Wochenschrift|2023

61 cit.

Current Senior Leaders

Wrote the book, still writing it

Papers

Sorafenib in Advanced Hepatocellular Carcinoma

New England Journal of Medicine|2008

13k cit.

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

Hepatology|2005

10.7k cit.

Management of Hepatocellular Carcinoma: An Update Δσ

Hepatology|2011

8.1k cit.

Management of Hepatocellular Carcinoma *

Hepatology|2005

5.9k cit.

Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference

Journal of Hepatology|2001

4.1k cit.

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Hepatology|2012

3.8k cit.

Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification

Seminars in Liver Disease|1999

3.8k cit.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet|2016

3.7k cit.

Hepatocellular carcinoma

The Lancet|2003

3.6k cit.

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

The Lancet|2002

3.5k cit.

Reagents for Liver Disease and Transplantation

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 67

Ki-67 (D3B5) Rabbit Monoclonal Antibody (Alexa Fluor® 555 Conjugate)

Cited in 5 papers

#20701$465

View Evidence →

Cell Signaling TechnologyEvidence 62

Bcl-3 (E2M6N) Rabbit Monoclonal Antibody

Cytokeratin 7

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 63

OB-Cadherin (16G5) Mouse Monoclonal Antibody

Cited in 9 papers

#13577$158,348

View Evidence →

Cell Signaling TechnologyEvidence 65

AMPK beta1 Antibody

Cited in 6 papers

#12063$317

View Evidence →

Cell Signaling Technology

Phospho-Jak2 (Tyr1008) (D4A8) Rabbit Monoclonal Antibody

Cited in 6 papers

#8082$178,412

View Evidence →